2019
Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment
Sen S, Ahmad Y, Dehbi HM, Howard JP, Iglesias JF, Al-Lamee R, Petraco R, Nijjer S, Bhindi R, Lehman S, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Härle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Silva PC, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J, Davies JE. Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment. Journal Of The American College Of Cardiology 2019, 73: 444-453. PMID: 30704577, PMCID: PMC6354033, DOI: 10.1016/j.jacc.2018.10.070.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsInstantaneous wave-free ratioFractional flow reserveLAD lesionsMyocardial infarctionUnplanned revascularizationLeft anterior descending (LAD) arteryEvent ratesLower myocardial infarctionAdverse cardiac eventsAnterior descending (LAD) arteryPhysiological assessmentLow event ratesMACE rateCardiac eventsCardiovascular deathClinical eventsFlow reserveHigh riskPatientsLesionsLADRevascularizationTrialsTreatment
2012
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Review Of Cardiovascular Therapy 2012, 10: 1471-1480. PMID: 23253272, DOI: 10.1586/erc.12.148.Peer-Reviewed Original ResearchConceptsNew oral anticoagulantsParoxysmal atrial fibrillationOral anticoagulantsNonparoxysmal atrial fibrillationAtrial fibrillationHeart failureStroke preventionNew anticoagulantsContemporary phase III trialsAdditional prognostic benefitPhase III trialsPresence of diabetesNew drugsImpact of genderIII trialsPrognostic benefitDiabetes mellitusAnticoagulantsPatientsWarfarinEvent ratesCardiovascular medicineFibrillationMellitusDiabetes